The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

Behavioral interventions for adolescents and young adults with type 2 diabetes or prediabetes

Ko AS, Michel AA, Wisk LE. Behavioral interventions for adolescents and young adults with type 2 diabetes or prediabetes. Curr Opin Pediatr. 2025 Mar 27.[...]

Incidence of chronic kidney disease among adults with prediabetes in the CURE-CKD registry, 2013-2020

Alicic RZ, Duru OK, Jones CR, Kornowske LM, Daratha KB, Reynolds CL, Pavkov ME, Koyama AK, Xu F, Nicholas SB, Neumiller JJ, Norris KC, Hennessey[...]

Managing a Rare Case of Methicillin-Resistant Staphylococcus aureus (MRSA) Holocord With Intravenous Antibiotics

Dao KT, Perera MX, Yip SA, Fox K. Managing a Rare Case of Methicillin-Resistant Staphylococcus aureus (MRSA) Holocord With Intravenous Antibiotics. Cureus. 2025 Mar 2;17(3):e79918.[...]